Given its significant role in tumor progression and metastasis, VEGFR-3 is a promising target for cancer therapy. Several therapeutic strategies are being explored, including monoclonal antibodies, small molecule inhibitors, and soluble receptors that can sequester its ligands. Inhibiting VEGFR-3 can potentially disrupt the lymphatic spread of cancer and improve patient outcomes.
